Skip to main content

Table 2 Univariate analysis of tumor markers

From: CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy

Tumor marker

Hazard ratio (95% CI)

P value

pre-AFU > 45.1

1.607 (0.504, 5.126)

0.423

pre-AFP > 2.6

1.294 (0.810, 2.066)

0.280

pre-CEA > 1.6

1.193 (0.841, 1.893)

0.322

pre-CA199 > 24.9

1.729 (1.187, 2.519)

0.004

pre-CA125 > 16

2.337 (1.515, 3.606)

0.000

pre-CA724 > 4.6

2.033 (1.391, 2.972)

0.000

post-AFU > 40.9

0.995 (0.517, 1.915)

0.988

post-AFP > 4.6

1.697 (0.958, 3.005)

0.070

post-CEA > 3.3

1.220 (0.813, 1.831)

0.337

post-CA199 > 62.6

2.447 (1.515, 3.954)

0.000

post-CA125 > 11.2

2.187 (1.352, 3.536)

0.001

post-CA724 > 5.9

2.246 (1.460, 3.455)

0.000

diff-AFU > 0

0.742 (0.290, 1.899)

0.533

diff-AFP > 0

1.017 (0.718, 1.439)

0.924

diff-CEA > 0

0.992 (0.814, 1.120)

0.940

diff-CA199 > 0

1.217 (1.000, 1.481)

0.050

diff-CA125 > 0

1.190 (0.932, 1.520)

0.163

diff-CA724 > 0

1.186 (0.946, 1.486)

0.139

  1. Units: AFU(U/L); AFP (ng/ml); CEA (ng/ml); CA199(U/ml); CA125(U/ml); CA724(U/ml)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us